Histone deacetylase inhibitors: Design, structure-activity relationships and therapeutic implications for cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 6, 2009, Pages 661-692

  Marson, Charles M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Benzamide; Cancer therapy; Cyclic peptide; HDAC isoform; Histone deacetylase (HDAC); Histone deacetylase inhibitor; Hydroxamate; Zinc binding group

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ADS 100380; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; CINNAMOHYDROXAMIC ACID DERIVATIVE; CRA 024781; CRA 026440; CYCLODEPSIPEPTIDE DERIVATIVE; DU 145; FLUDARABINE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IMATINIB; ISOTRETINOIN; KETONE DERIVATIVE; MIDOSTAURIN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NVP LBH 8589; PANOBINOSTAT; PLACEBO; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RETINOIC ACID; ROMIDEPSIN; TANESPIMYCIN; THIOL DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FUNCTION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON TUMOR; COLORECTAL CANCER; CONSTIPATION; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DYSGEUSIA; ELECTROCARDIOGRAPHY; ENZYME ACTIVE SITE; FATIGUE; FOOD; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEMATOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LETHARGY; LEUKEMIA; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LUNG CANCER; LUNG EMBOLISM; LYMPHOCYTOPENIA; MELANOMA; MOLECULAR MODEL; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN TARGETING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; TREATMENT DURATION;

EID: 70349128205     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009788679976     Document Type: Review

References (196)

1. Zhang, W.; Bieker, J. Acetylation and modulation of erythroid Krüppel-like factor (EKLF) activity by interaction with histone acetyltransferases J. Proc. Natl. Acad. Sci. USA, 1998, 95, 9855-9860.
2. Pazin, M. J.; Kadonaga, J. T. What's up and down with histone deacetylation and transcription? Cell, 1997, 89(3), 325-328.
3. Marmorstein, R. Protein modules that manipulate histone tails for chromatin regulation. Nat. Rev. Mol. Cell. Biol., 2001, 2(6), 422-432.
4. Roth, S. Y.; Denu, J. M.; Allis, C. D. Histone acetyl transferases. Annu. Rev. Biochem., 2001, 70, 81
5. Iizuka, M.; Smith, M. M. Functional consequences of histone modifications. Curr. Opin. Genet. Dev., 2003, 13(2), 154-160.
6. Schaefer, S.; Jung, M. Chromatin modifications as targets for new anticancer drugs. Arch. Pharm., 2005, 338, 347-357.
7. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug. Discov., 2006, 5, 37-50.
8. Biel, M.; Wascholowski, V.; Giannis, Epigenetics - An epicenter of gene regulation: Histones and histone-modifying enzymes A. Angew. Chem., Int. Ed., 2005, 44, 3186-3216.
9. Rodriquez, M.; Aquino, M.; Bruno, I.; De Martino, G.; Taddei, M.; Gomez-Paloma, L. Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors. Curr. Med. Chem., 2006, 13, 1119-1139.
10. Grozinger, C. M.; Schreiber, S. L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors Chem. Biol., 2002, 9, 3-16.
11. Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J., 2000, 19, 1176-1179.
12. Luo, J.; Nikoaev, A. Y.; Imai, S.; Chen, D.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell, 2001, 107, 137-148.
13. Ito, A.; Kawaguchi, Y.; Lai, C. H.; Kovacs, J. J.; Higashimoto, Y.; Appella, E.; Yao, T. P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J., 2002, 21, 6236-6245.
14. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA, 2003, 100, 4389-4394.
15. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.; Yao, T. HDAC6 is a microtubule-associated deacetylase. Nature, 2002, 417, 455-458.
16. Gantt, S. L.; Gattis, S. G.; Fierke, C. A. Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry, 2006, 45(19), 6170-6178.
17. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 1999, 401, 188-193.
18. Nielsen, K.; Hildmann, C.; Dickmanns, A.; Schwienhorst, A.; Ficner, R. Crystal structure of a bacterial class 2 histone deacetylase homologue. J. Mol. Biol., 2005, 354, 107-120.
19. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkühler, C. D.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA, 2004, 101, 15064-15069.
20. Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B.-C..; Verner, E.; Wynands, R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.; McRee, D.E.; Tari, L.W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure, 2004, 12, 1325-1334.
21. Wang, D.-F.; Helquist, P.; Wiech, N. L.; Wiest, O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J. Med. Chem., 2005, 48, 6936-6947.
22. Wang, D.-F.; Wiest, O.; Helquist, P.; Lan-Hargest, H.-Y.; Wiech, N. L. On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J. Med. Chem., 2004, 47, 3409-3417.
23. Kapustin, G. V.; Fejer, G.; Gronlund, J. L.; McCafferty, D. G.; Seto, E.; Etzkorn, F. A. Phosphorus-based SAHA analogues as histone deacetylase inhibitors. Org. Lett., 2003, 5, 3053-3056.
24. Corminboeuf, C.; Hu, P.; Tuckerman, M. E.; Zhang, Y. Unexpected deacetylation mechanism suggested by a density functional theory QM/MM study of histone-deacetylase-like protein. J. Am. Chem. Soc., 2006, 128, 4530-4531.
25. Parkin, G. Synthetic analogues relevant to the structure and function of zinc enzymes. Chem. Rev., 2004, 104, 699-767.
26. Ragno, R.; Simeoni, S.; Valente, S.; Massa, S.; Mai, A. 3-D QSAR studies on histone deacetylase inhibitors. A GOLPE/GRID approach on different series of compounds. J. Chem. Inf. Model., 2006, 46, 1420-1430.
27. Brehm, A.; Miska, E. A.; McCance, D. J.; Reid, J. L.; Bannister, A. J.; Kouzarides, T. Micromolded PDMS planar electrode allows patch clamp electrical recordings from cells. Nature, 1998, 391, 597-604.
28. Robertson, K. D.; Ait-Si-Ali, S.; Yokochi, T.; Wade, P. A.; Jones, P. L.; Wolffe, A. P. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet., 2000, 25, 338-342.
29. Kao, H. Y.; Downes, M.; Ordentlich, P.; Evans, R. M. Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes Dev., 2000, 14, 55-66.
30. Miska, E. A.; Karlsson, C.; Langley, E.; Nielsen, S. J.; Pines, J.; Kouzarides, T. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J., 1999, 18, 5099-5107.
31. Yang, W.-M.; Tsai, S.-C.; Wen, Y.-D.; Fejer, G.; Set, E. Functional domains of histone deacetylase-3. J. Biol. Chem., 2002, 277, 9447-9454
32. Roy, S.; Packman, K.; Jeffrey, R.; Tenniswood, M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ., 2005, 12, 482-491.
33. Thevenet, L.; Mejean, C.; Moniot, B.; Bonneaud, N.; Galeotti, N.; Aldrian-Herrada, G.; Poulat, F.; Berta, P.; Benkirane, M.; Boizet-Bonhoure, B. Regulation of human SRY subcellular distribution by its acetylation/deacetylation. EMBO J., 2004, 23, 3336-3345.
34. Masumoto, H.; Hawke, D.; Kobayashi, R.; Verreault, A. A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature, 2005, 436, 294-298.
35. Song, J.; Noh, J. H.; Eun, J. W.; Ahn, Y. M.; Kim, S. Y.; Lee, S. H.; Park, W. S.; Yoo, N. J.; Lee, J. Y.; Nam, S. W. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS, 2005, 113, 264-268.
36. Fraga, M. F.; Ballestar, E.; Villar-Garea, A.; Boix-Chornet, M.; Espada, J.; Schotta, G.; Bonaldi, T.; Haydon, C.; Ropero, S.; Petrie, K.; Iyer, N. G.; Perez-Rosado, A.; Calvo, E.; Lopez, J. A.; Cano, A.; Calasanz, M. J.; Colomer, D.; Piris, M. A.; Ahn, N.; Imhof, A.; Caldas, C.; Jenuwein, T.; Esteller, M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet., 2005, 37, 391-400.
37. Zhu, P.; Martin, E.; Mengwasser, J.; Schlag, P.; Janssen, K. P.; Gottlicher, M. Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2. Cancer Cell, 2004, 5, 455-464.
38. Lin, R. J.; Evans, R. M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell, 2000, 5, 821-830.
39. Amann, J. M.; Nip, J.; Strom, D. K.; Lutterbach, B.; Harada, H.; Lenny, N.; Downing, J. R.; Meyers, S.; Hiebert, S. W. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol. Cell Biol., 2001, 21, 6470-6483.
40. David, G.; Alland, L.; Hong, S. H.; Wong, C. W.; DePinho, R. A.; Dejean, A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene, 1998, 16, 2549-2556.
41. Dhordain, P.; Lin, R. J.; Quief, S.; Lantoine, D.; Kerckaert, J. P.; Evans, R. M.; Albagli, O. The LAZ3(BCL-6) oncoprotein recruits a SMRT/ mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucl. Acids Res., 1998, 26, 4645-4651.
42. Van Lint, C.; Emiliani, S.; Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr., 1996, 5, 245-253.
43. Liu, T.; Kuljaca, S.; Tee, A.; Marshall, G. M. Histone deacetylase inhibitors: Multifunctional anticancer agents Cancer Treat. Rev., 2006, 32, 157-165.
44. Rosato, R. R.; Almenara, J. A.; Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res., 2003, 63, 3637-3645.
45. Butler, L. M.; Agus, D. B.; Scher, H. I.; Higgins, B.; Rose, A.; Cordon-Cardo, C.; Thaler, H. T.; Rifkind, R. A.; Marks, P. A.; Richon, V. M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res., 2000, 60, 5165-5170.
46. Mahlknecht, U.; Hoelzner, D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol. Med., 2000, 6, 623-644
47. Gayther, S. F.; Daigo, Y.; Russell, P.; Wilson. A.; Sowter, H. M.; Delhanty, J. D.; Ponder, B. A.; Kouzarides, T.; Caldas, C. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet., 2000, 24, 300-303.
48. Archer, S. Y.; Meng, S.; Shei, A.; Hodin, R. A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA, 1998, 95, 6791-6796.
49. Fournel, M.; Trachy-Bourget, M. C.; Yan, P. T.; Kalita, A.; Bonfils, C.; Beaulieu, C.; Frechette, S.; Leit, S.; Abou-Khalil, E.; Woo, S. H.; Delorme, D.; MacLeod, A. R.; Besterman, J. M.; Li, Z. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res., 2002, 62, 4325-4330.
50. Johnstone, R. W.; Licht, J. D. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell, 2003, 4, 13-18.
51. Lipinski, M. M.; Jacks, T. The retinoblastoma gene family in differentiation and development. Oncogene 1999, 18, 7873-7882.
52. Kwon, S. H.; Ahn, S. H.; Kim, Y. K.; Bae, G.-U.; Yoon, J. W.; Hong, S.; Lee, H. Y.; Lee, Y.-W.; Lee, H.-W.; Han, J.-W. Activation of p21(WAF1-Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin - Involvement of protein kinase C. J. Biol. Chem., 2001, 276, 42084-42090. 53 Druesne-Pecollo, N.; Pagniez, A.; Thomas, M.; Cherbuy, C.; Duée, P. H.; Martel, P.; Chaumontet, C. Diallyl disulfide increases CDKN1A promoter-associated histone acetylation in human colon tumor cell lines. J. Agric. Food Chem., 2006, 54, 7503-7507.
53. Whetstine, J. R.; Ceron, J.; Ladd, B.; Dufourcq, P.; Reinke, V.; Shi, Y. Regulation of tissue-specific and extracellular matrix-related genes by a class I histone deacetylase. Mol. Cell, 2005, 18, 483-490.
54. Mikhailov, A.; Shinohara, M.; Rieder, C. L. Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J. Cell Biol., 2004, 166, 517-526.
55. Toh, Y.; Ohga, T.; Endo, K.; Adachi, E.; Kusumoto, H.; Haraguchi, M.; Okamura, T.; Nicolson, G. L. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int. J. Cancer, 2004, 110, 362-367.
56. Wang, S.; Yan-Neale, Y.; Fischer, D.; Zeremski, M.; Cai, R.; Zhu, J.; Asselbergs, F.; Hampton, G.; Cohen, D. Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line. Oncogene, 2003, 22, 6204-6213.
57. Joseph, J.; Mudduluru, G.; Antony, S.; Vashistha, S.; Ajitkumar, P.; Somasundaram, K. Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes. Oncogene, 2004, 23, 5284-5292.
58. Varambally, S.; Dhanasekaran, S. M.; Zhou, M.; Barrette, T. R.; Kumar-Sinha, C.; Sanda, M. G.; Ghosh, D.; Pienta, K. J.; Sewalt, R. G. A. B.; Otte, A. P.; Rubin, M. A.; Chinnaian, A. M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature, 2002, 419, 624-629.
59. Kim, S. H.; Ahn, S.; Han, J. W.; Lee, H. W.; Lee, H. Y.; Lee, Y. W.; Kim, M. R.; Kim, W. B.; Hong, S. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem. Biophys. Res. Commun., 2004, 315, 964-970.
60. Tang, X. X.; Robinson, M. E.; Riceberg, J. S.; Kim, D. Y.; Kung, B.; Titus, T. B.; Hayashi, S.; Flake, A. W.; Carpentieri, D.; Ikegaki, N. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin. Cancer Res., 2004, 10, 4822-4830.
61. Kim, M. S.; Kwon, H. J.; Lee, Y. M.; Baek, J. H.; Jang, J. E.; Lee, S. W.; Moon, E. J.; Kim, H. S.; Lee, S. K.; Chung, H. Y.; Kim, C. W.; Kim, K. W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med., 2001, 7, 437-443.
62. Kato, H.; Tamamizu-Kato, S.; Shibasaki, F. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J. Biol. Chem., 2004, 279, 41966-41974.
63. Zgouras, D.; Wachtershauser, A.; Frings, D.; Stein, J. Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1alpha nuclear translocation. Biochem. Biophys. Res. Commun., 2003, 300, 832-838.
64. Zgouras, D.; Becker, U.; Loitsch, S.; Stein. Modulation of angiogenesis-related protein synthesis by valproic acid J. Biochem. Biophys. Res. Commun., 2004, 316, 693-697.
65. Deroanne, C. F.; Bonjean, K.; Servotte, S.; Devy, L.; Colige, A.; Clausse, N.; Blacher, S.; Verdin, E.; Foidart, J. M.; Nusgens, B. V.; Castronovo, V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 2002, 21, 427-436.
66. Qian, D. Z.; Wang, X.; Kachhap, S. K.; Kato, Y.; Wei, Y.; Zhang, L.; Atadja, P.; Pili, R. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res., 2004, 64, 6626-6634.
67. Insinga, A.; Monestiroli, S.; Ronzoni, S.; Gelmetti, V.; Marchesi, F.; Viale, A.; Altucci, L.; Nervi, C.; Minucci, S.; Pellici, P. G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med., 2005, 11, 71-76.
68. Ngo, L.; Holmgren, A.; Jiang, X.; Marks, P. A. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA, 2005, 102, 673-678.
69. Marks, P. A.; Jiang, X.-J. Ozone therapy effects on biomarkers and lung function in asthma. Cell Cycle, 2005, 4, 549-554.
70. Sonnemann, H.; Hartwig, M.; Plath, A.; Kumar, K. S.; Muller, C.; Beck, J. F. Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Lett., 2006, 232, 148-160.
71. Gillespie, S.; Borrow, J.; Xu, D. Z.; Hersey, P. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis, 2006, 11, 2251-2261.
72. Nebbioso, A.; Clarke, N.; Voltz, E.; Germain, E.; Ambrosino, C.; Bontempo, P.; Alvarez, R.; Schiavone, E. M.; Ferrara, F.; Besciani, F.; Weisz, A.; de Lera, A. R.; Gronemeyer, H.; Altucci, L. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med., 2005, 11, 77-84.
73. Xu, W. S.; Ngo, L.; Perez, G.; Dokmanovic, M.; Marks, P. A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc. Natl. Acad. Sci. USA, 2006, 103, 15540-15545.
74. Komatsu, N.; Kawamata, N.; Takeuchi, S.; Yin, D.; Chien, W. W.; Miller, C. W.; Koeffler, H. P. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol. Reports, 2006, 15, 187-191.
75. Gediya, L. K.; Chopra, P.; Purushottamachar, P.; Maheshwari, N.; Njar, C. O. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J. Med. Chem., 2005, 48, 5047-5051.
76. Wang, S. W.; Yan-Neale, Y.; Cai, R.; Alimov, I.; Cohen, D. Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle, 2006, 5, 1662-1668.
77. Rosato, R. R.; Maggio, S. C.; Almenara, J. A.; Payne, S. G.; Atadja, P.; Spiegel, S.; Dent, P.; Grant, S. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol. Pharmacol., 2006, 69, 216-225.
78. Takai, N.; Ueda, T.; Nishida, M.; Nasu, K.; Narahara, H. Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells. Anticancer Res., 2006, 26, 939-945.
79. Sato, T.; Suzuki, M.; Sato, Y.; Echigo, S.; Rikiishi, H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int. J. Oncol., 2006, 28, 1233-1241.
80. Kim, Y. K.; Lee, E. K.; Kang, J. K.; Kim, J. A.; You, J.-S.; Park, J. H.; Seo, D.-W.; Hwang, J. W.; Kim, S.-N.; Lee, H. Y.; Lee, H. W.; Han, J.-W. Activation of NF-kappaB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: its implication for resistance to apoptosis. Cell Death Differ., 2006, 13, 2033-2041.
81. Watanabe, T.; Hioki, M; Fujiwara, T.; Nishizaki, M.; Kagawa, S.; Taki, M.; Kishimoto, H.; Endo, Y.; Urata, Y.; Tanaka, N.; Fujiwara, T. Comparative potency of different UV sources in reducing the density and antigen-presenting capacity of Langerhans cells in C3H mice. Exp. Res., 2006, 312, 256-261.
82. Saunders, L. R.; Verdin, E. Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors. Mol. Cancer Ther., 2006, 5, 2777-2785.
83. Lin, H.-Y.; Chen, C.-S.; Lin, S.-P.; Weng, J.-R.; Chen, C.-S. Targeting histone deacetylase in cancer therapy. Med. Res. Rev., 2006, 26, 397-413.
84. Lichenstein, H.; Jeffers, M. Combination therapies using HDAC inhibitors. WO 2006/082428.
85. Dowdy, S. C.; Jiang, S. J.; Zhou, X. C.; Hou, X. N.; Jin, F.; Podratz, K. C.; Jiang, S. W. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol. Cancer Ther., 2006, 5, 2767-2776.
86. Tabe, Y.; Konopleva, M.; Contractor, R.; Munsell, M.; Schober, W. D.; Jin, L.; Tsutsumi-Ishii, Y.; Nagaoka, I.; Igari, J.; Andreeff, M. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood, 2006, 107, 1546-1554.
87. Kano, Y.; Akutsu, M.; Tsunoda, S.; Izumi, T.; Kobayashi, H.; Mano, H.; Furakawa, Y. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Invest. New Drugs, 2007, 25, 31-40.
88. Olsen, E.; Kim, Y. H.; Kuzel, T.; Pacheco, T. R.; Foss, F.; Parker, S.; Wang, J. G.; Frankel, S. R.; Lis, J.; Duvic Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial M. J. Clin. Oncol., 2006, 24, 422S Abstract 7500.
89. Fakih, M. G.; Pendyala, L.; Toth, K.; Creaven, P.; Soehnlein, N.; Litwin, A.; Trump, D. A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC). J. Clin. Oncol., 2006, 24, 168S.
90. Ramalingam, S.; Parise, R. A.; Egorin, M. J.; Argiris, A.; Stoller, R.; Beattie, L.; Aparicio, A.; Newman, E. M.; Zweibel, J.; Belani, C. P. Phase I study of vorinostat, a histone deacetylase (HDAC) inhibitor, in combination with carboplatin (Cb) and paclitaxel (P) for patients with advanced solid malignancies (NCI #6922). J. Clin. Oncol., 2006, 24, 98S.
91. Munshi, A.; Tanaka, T.; Hobbs, M. L.; Tucker, S. L.; Richon, V. M.; Meyn, R. E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer Ther., 2006, 5, 1967-1974.
92. Kelly, W. K.; Richon, V. M.; O'Connor, O.; Curley, T.; MacGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J. H.; Rifkind, R.; Marks, P. A.; Scher, H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res., 2003, 9, 3578-3588.
93. Qian, X.; LaRochelle, W. J.; Ara, G.; Wu, F.; Petersen, K. D.; Thougaard, A.; Sehested, M.; Lichenstein, H. S.; Jeffers, M. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol. Cancer Ther., 2006, 5, 2086-2095.
94. Steele, N.; Vidal, J.; Plumb, J.; Attard, G.; Rasmussen, A.; Buhl-Jensen, P.; Brown, R.; Blagden, S.; Evans, J.; de Bono, J. A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours. J. Clin. Oncol., 2005, 23, 200S.
95. Hansen, M.; Gimsing, P.; Rasmussen, A.; Buhl-Jensen, P.; Knudsen, L. M. A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors. J. Clin. Oncol., 2005, 23, 225S.
96. Remiszewski, S. W.; Sambucetti, L. C.; Bair, K. W.; Bontempo, J.; Cesarz, D.; Chadramouli, N.; Chen, R.; Cheung, M.; Cornell-Kennon, S.; Dean, K.; Diamantidis, G.; France, D.; Green, M. A.; Howell, K. L.; Kashi, R.; Kwon, P.; Lassota, P.; Martin, M. S.; Mou, Y.; Perez, L. B.; Sharma, S.; Smith, T.; Sorensen, E.; Taplin, F.; Trogani, N.; Versace, R.; Walker, H.; Weltchek-Engler, S.; Wood, A.; Wu, A.; Atadja, P. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo anti-tumor activity: discovery of (2E)-N-hydroxy-3-[4-(2-hydroxyethyl)[2-(1H-indol-3-yl) ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J. Med. Chem., 2003, 46, 4609-4624.
97. Remiszewski, S. W. The discovery of NVP-LAQ824: from concept to clinic. Curr. Med. Chem., 2003, 10, 2393-2402.
98. Ottmann, O. G.; Deangelo, D. J.; Stone, R. M.; Pfeifer, H.; Atadja, P.; Peng, B.; Scott, J. W.; Dugan, M.; Sonneveld, P. A phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. J. Clin. Oncol., 2004, 22, 201S.
99. Rowinsky, E. K.; Pacey, S.; Patnaik, A.; O'Donnell, A.; Mita, M. M.; Atadja, P.; Peng, B.; Dugan, M.; Scott, J. W.; de Bono, J. S. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors. J. Clin. Oncol., 2004, 22, 200S.
100. Fischer, T.; Patnaik, A.; Bhalla, K.; Beck, J.; Morganroth, J.; Laird, G. H.; Sharma, S.; Scott, J. W.; Dugan, M.; Giles, F. Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies. J. Clin. Oncol., 2005, 23, 218S.
101. Beck, J.; Fischer, George, D.; Huber, C.; Calvo, E.; Atadja, P.; Peng, B.; Kwong, C.; Sharma, S.; Patnaik, A. HDAC inhibition in cancer therapy: an increasingly intriguing tale of chemistry, biology and clinical benefit. J. Clin. Oncol., 2007, 23, 16S, Abstr. 3418.
102. Wiedemann, M.; Bluethner, T.; Niederhagen, M.; Schoppmeyer, K.; Moessner, J.; Caca, K. Two novel histone deacetylase inhibitors NVP-LAQ824 and NVP-LBH589 are active against biliary tract cancer and potentiate the efficacy of gemcitabine. J. Clin. Oncol., 2006, 24, 214S.
103. Fiskus, W.; Pranpat, M.; Balasis, M.; Atadja, P.; Manley, P.; Giles, F.; Bhalla, K. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against unmutated or mutant Bcr-Abl-expressing human leukemia cells. J. Clin. Oncol., 2006, 24, 359S.
104. Buggy, J. J.; Cao, Z. A.; Bass, K. E.; Verner, E.; Balasubramanian, S.; Liu, L.; Schultz, B. E.; Young, P.; Dalrymple, S. A. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol. Cancer. Ther., 2006, 5, 1309-1317.
105. Cao, Z. A.; Bass, K. E.; Balasubramanian, S.; Liu, L.; Schultz, B.; Verner, E.; Dai, Y.-Q.; Molina, R. A.; Davis, J. R.; Misialek, S.; Sendzik, M.; Orr, C. J.; Leung, L.; Callan, O.; Young, P.; Dalrymple, S. A.; Buggy, J. J. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Mol. Cancer. Ther., 2006, 5, 1693-1701.
106. Hauschild, A.; Trefzer, U.; Garbe, C.; Kaehler, K.; Ugurel, S.; Kiecker, F.; Eigentler, T.; Krissel, H.; Schadendorf, D. A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. J. Clin. Oncol., 2006, 24, 463S.
107. Donovan, E. A.; Sparreboom, A.; Figg, W.; Trepel, J.; Maynard, K.; Zwiebel, J.; Melillo, G.; Gutierrez, M.; Doroshow, J.; Kummar, S. Phase I trial of the oral histone deacetylase inhibitor MS-275 administered with food. ASCO Meeting Abstracts. June 20 2006, 13036.
108. Donovan, E. A.; Ryan, Q.; Acharya, M.; Chung, E.; Trepel, J.; Murgo, A.; Melillo, G.; Conley, B. Phase I pharmacokinetic-pharmacodynamic trial of weekly MS-275, an oral histone deacetylase inhibitor. J. Clin. Oncol., 2005, 23, 215S.
109. Pili, R.; Rudek, M.; Altiok, S.; Qian, D.; Zhao, M.; Donehower, R.; Anderson, A.; Halter, M.; McFarland, H.; Zwiebel, J.; Carducci, M. Phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis retinoic acid in patients with advanced solid tumors. J. Clin. Oncol., 2006, 24, 134S.
110. Simonini, M. V.; Camargo, L. M.; Dong, E.; Maloku, E.; Costa, E.; Guidotti, A. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl. Acad. Sci. USA, 2006, 103, 1587-1592.
111. Garcia-Manero, G.; Minden, M.; Estrov, Z.; Verstovsek, S.; Newsome, W. M.; Reid, G.; Besterman, J.; Li, Z.; Pearce, L.; Martell, R. Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS). J. Clin. Oncol., 2006, 24, 337S.
112. Carducci, M.; Siu, L. L.; Sullivan, R.; Maclean, M.; Kalita, A.; Chen, E. X.; Pili, R.; Martell, R. E.; Besterman, J.; Reid, G. K. Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors. J. Clin. Oncol., 2006, 24, 122S.
113. Gelmon, K.; Tolcher, A.; Carducci, M.; Reid, G. K.; Li, Z.; Kalita, A.; Callejas, V.; Longstreth, J.; Besterman, J. M.; Siu, L. L. Phase I trials of the oral histone deacetylase (HOAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors. J. Clin. Oncol., 2005, 23, 228S.
114. Li, Z.; Zhou, N.; Fournel, M.; Kalita, A.; Trachy-Bourget, M.-C.; Yan, P. T.; Lu, A.; Elowe, N.; Hou, Y.; Liu, J.; Bonfils, C.; Robert, M.-F.; Leit, S.; Raeppel, S.; Frechette, S.; Rahil, G.; Wang, J.; Delorme, D.; Moradei, O.; MacLeod, R.; Besterman, J. M. 83 Anti-tumor activities of MGCD0103, a novel isotype-selective histone deacetylase inhibitor. Eur. J. Cancer Suppl. 16th EORTC-NCI-AACR Symp. Mol. Targets Cancer Ther., 2004, 2(8), Abstr 83.
115. Molife, R.; Patterson, S.; Riggs, C.; Higano, C.; Stadler, W. M.; Dearnley, D.; Parker, C.; McCulloch, W.; Shalaurov, A.; de Bono, J. S. Phase II study of FK228 in patients with hormone refractory prostate cancer (HRPC). ASCO Meeting Abstracts. June 20, 2006, 14554.
116. Piekarz, R. L.; Robey, R.; Sandor, V.; Bakke, S.; Wilson, W. H.; Dahmoush, L.; Kingma, D. M.; Turner, M. L.; Altemus, R.; Bates, S. E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood, 2001, 98, 2865-2868.
117. Piekarz, R. L.; Frye, R.; Turner, M.; Wright, J.; Leonard, J.; Allen, S.; Smith, S.; Kischbaum, M.; Zain. J.; Bates, S. E. Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228. J. Clin. Oncol., 2005, 24, 207S.
118. Whittaker, S.; McCulloch, W.; Robak, T.; Baran, E.; Prentice, A. International multicenter phase II study of the HDAC inhibitor (HDACi) depsipeptide (FK228) in cutaneous T-cell lymphoma (CTCL): Interim report. J. Clin. Oncol., 2006, 24, 136S.
119. Piekarz, R. L.; Frye, R.; Turner, M.; Wright, J.; Leonard, J.; Allen, S.; Bates, S. E. Update on the phase II trial and correlative studies of depsipeptide in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. ASCO Meeting Abstracts. Jul 15, 2004, Abstr. 3028.
120. Sasakawa, Y.; Naoe, Y.; Inoue, T.; Sasakawa, T.; Matsuo, M.; Manda, T.; Mutoh, S. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem. Pharmacol., 2002, 6, 1079-1090.
121. Piekarz, R. L.; Frye, A. R.; Wright, J. J.; Steinberg, S. M.; Liewehr, D. J.; Rosing, D. R.; Sachdev, V.; Fojo, T.; Bates, S. E. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin. Cancer Res., 2006, 12, 3762-3773.
122. Ueda, H.; Nakajima, H.; Hori, Y.; Fujita, T.; Mishimura, M.; Goto, T.; Okuhara, M. F. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot., 1994, 47, 301-310.
123. Hirokowa, Y.; Nakajima, H.; Hanemann, C. O.; Kurtz, A.; Frahm, S.; Mautner, V.; Maruta, H. Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228. Cancer Biol. Ther., 2005, 4, 379-381.
124. Kobayashi, Y; Ohtsuki, M; Murakami, T.; Kobayashi, T.; Sutheesophon, K.; Kitayama, H.; Kano, Y.; Kusano, E.; Nakagawa, H.; Furukawa, Y. Apoptotic markers in various stages of amygdala kindled seizures in rats. Oncogene, 2006, 25, 512-518.
125. Robey, R. W.; Zhan, Z. R.; Piekarz, R. L.; Kayastha, G. L.; Fojo, T.; Bates, S. E. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin. Cancer Res., 2006, 12, 1547-1555.
126. Meerman, J. H. Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: the role of N,O-sulfonation in chemical carcinogenesis of aromatic amines. Environ. Health Perspect., 1983, 49, 27-32.
127. Remiszewski, S. W.; Sambucetti, L. C.; Atadja, P.; Bair, K. W.; Cornell, W. D.; Green, M. A.; Howell, K. L.; Jung, M.; Kwon, P.; Trogani, N.; Walker, H. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem., 2002, 45, 753-757.
128. Van Ommeslaeghe, K.; Elaut, G.; Brecx, V.; Papeleu, P.; Iterbeke, K.; Geerlings, P.; Tourwé, D.; Rogiers, V. Amide analogues of TSA: synthesis, binding mode analysis and HDAC inhibition. Bioorg. Med. Chem. Lett., 2003, 13, 1861-1864.
129. Kim, D.-K.; Lee. J. Y.; Kim, J.-S.; Ryu, J.-H.; Choi, J.-Y.; Lee, J. W.; Im, G.-J.; Kim, T.-K.; Seo, J. W.; Park, H.-J.; Yoo, J.; Park, J.-H.; Kim, T.-Y.; Bang, Y.-J. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. J. Med. Chem., 2003, 46, 5745-5751.
130. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.-H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res., 2002, 62, 4916-4921.
131. Charrier, C.; Bertrand, P.; Gesson, J.-P.; Roche, J. Synthesis of rigid trichostatin A analogs as HDAC inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5339-5344.
132. Shinji, C.; Maeda, S.; Imai, K.; Yoshida, M.; Hashimoto, Y.; Miyachi, H. Design, synthesis, and evaluation of cyclic amide/imidebearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem., 2006, 14, 7625-7651.
133. Chen, B.; Petukhov, P. A.; Jung, M.; Velena, A.; Eliseeva, E.; Dritschilo, A.; Kozikowski, A. P. Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 1389-1392.
134. Woo, S. H.; Frechette, S.; Khalil, E. A.; Bouchain, G.; Vaisburg, A.; Bernstein, N.; Moradei, O.; Leit, S.; Allan, M.; Fournel, M.; Trachy-Bourget, M.-C.; Li, Z.; Besterman, J. M.; Delorme, D. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J. Med. Chem., 2002, 45, 2877-2885.
135. Cho, J.-W.; Lim, S.-C. Oxazole hydroxamic acid derivatives and use thereof. WO 2006/075888.
136. Guidi, A.; Dimoulas, T. N-Hydroxyamides omega-substituted with tricyclic groups as histone deacetylase inhibitors, their preparation and use in pharmaceutical formulations. WO 2006/097449 Menarini International Operations SA.
137. Frey, R. R.; Wada, C. K.; Garland, R. B.; Curtin, M. L.; Li, J.; Pease, L. J.; Glaser, K. B.; Marcotte, P. A.; Bouska, J. J.; Murphy, S. S.; Davidsen, S. K. Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett., 2002, 12, 3443-3447.
138. Marson, C. M.; Mahadevan, T.; Dines, J.; Sengmany, S.; Morrell, J. M.; Alao, J. P.; Joel, S. P.; Vigushin, D. M.; Coombes, R. C. Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett., 2007, 17, 136-141.
139. Mrris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-1662.
140. Hoffmann, K.; Brosch, G.; Loidl, P.; Jung, M. First non-radioactive assay for in vitro screening of histone deacetylase inhibitors. Pharmazie, 2000, 55, 601-606.
141. Marson, C. M.; Savy, P.; Rioja, A. S.; Mahadevan, T.; Mikol, C.; Veerupillai, A.; Nsubuga, E.; Chahwan, A.; Joel, S. P. Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J. Med. Chem., 2006, 49, 800-805.
142. Glenn, M. P.; Kahnberg, P.; Boyle, G. M.; Hansford, K. A.; Hans, D.; Martyn, A. C.; Parsons, P. G.; Fairlie, D. P. Antiproliferative and phenotype-transforming antitumor agents derived from cysteine. J. Med. Chem., 2004, 47, 2984-2994.
143. Varghese, S.; Gupta, D.; Baran, T.; Jiemjit, A.; Gore, S. D.; Casero, Jr., R. A.; Woster, P. M. Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors. J. Med. Chem., 2005, 48, 6350-6365.
144. Marson, C. M.; Serradji, N.; Rioja, A. S.; Gastaud, S. P.; Alao, J. P.; Coombes, R. C.; Vigushin, D. M. Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg. Med. Chem. Lett., 2004, 14, 2477-2481.
145. Wiech, N. L.; Lan-Hargest, H.-Y. Histone deacetylase inhibitors. WO 2006/ 052916.
146. Belvedere, S.; Miller, T. A. Histone deacetylase inhibitors. WO 2006/ 020004.
147. Ishibashi, N.; Sawada, Y. Hydroxyamide compounds having activity as inhibitors of histone deacetylase. WO 2006/016680.
148. Mai, A.; Massa, S.; Rotili, D.; Simeoni, S.; Ragno, R.; Botta, G.; Nebbioso, A.; Miceli, M.; Altucci, L.; Brosch, G. Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J. Med. Chem., 2006, 49, 6046-6056.
149. Deng, W.; Chen, D. Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (HDAC) inhibitors. WO 2006/101456.
150. Maier, T.; Baer, T. Sulfonylpyrroles as histone deacetylase inhibitors. WO 2006/105979.
151. Maier, T.; Baer, T. N-Sulfonylpyrroles as histone deacetylase inhibitors. WO 2006/097474.
152. Moffat, D. F. C.; Patel, S. R. Histone deacetylase inhibitors. WO 2006/ 123121.
153. Angibaud, P. R.; Marconnet-Decrane, L., Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase. WO 2006/122926.
154. Verdonck, M. G. C.; Angibaud, P. R. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase. WO 2006/010750.
155. Anandan, S. K.; Xiao, X.-Y. Fused heterocyclic compounds useful as inhibitors of histone deacetylase. WO 2006/088949.
156. Price, S.; Bordogna, W.; Bull, R. J.; Clark, D. E.; Crackett, P. H.; Dyke, H. J.; Gill, M.; Harris, N. V.; Gorski, J.; Lloyd, J.; Lockey, P. M.; Mullett, J.; Roach, A. G.; Roussel, F.; White, A. B. Identification and optimisation of a series of substituted 5-pyridin-2-ylthiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 363-369.
157. Price, S.; Bordogna, W.; Braganza, R.; Bull, R. J.; Dyke, H. J.; Gardan, S.; Gill, M.; Harris, N. V.; Heald, R. A.; van den Heuvel, M.; Lockey, P. M.; Lloyd, J.; Molina, A. G.; Roach, A. G.; Roussel, F.; Sutton, J. M.; White, A. B. Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 363-369.
158. Methot, J.; Miller, T. A. Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions. WO 2006/ 115833 Merck & Co Inc.
159. Hubbs, J. L.; Kattar, S. Benzothiophene hydroxamic acid derivatives. WO 2006/115835 Merck & Co Inc.
160. Suzuki, T.; Miyata, N. Non-hydroxamate histone deacetylase inhibitors. Curr. Med. Chem., 2005, 12, 2867-80.
161. Suzuki, T.; Miyata, N. Rational design of non-hydroxamate histone deacetylase inhibitors. Mini-Rev. Med. Chem., 2006, 6, 515-526.
162. Leit de Moradei, S. M.; Tessier, P. Inhibitors of histone deacetylase. WO 2006/102760 MethylGene, Inc.
163. Wada, C. K.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Garland, R. B.; Holms, J. H.; Li, J.; Pease, L. J.; Guo, J.; Glaser, K. B.; Marcotte, P. A.; Richardson, P. L.; Murphy, S. S.; Bouska, J. J.; Tapang, P.; Magoc, T. J.; Albert, D. H.; Davidsen, S. K.; Michaelides, M. R. Alpha-keto amides as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett., 2003, 13, 3331-3335.
164. Vasudevan, A.; Ji, Z.; Frey, R. R.; Wada, C. K.; Steinman, D.; Heyman, H. R.; Guo, Y.; Curtin, M. L.; Guo, J.; Li, J.; Pease, L.; Glaser, K. B.; Marcotte, P. A.; Bouska, J. J.; Davidsen, S. K.; Michaelides, M. R. Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett., 2003, 13, 3909-3913.
165. Suzuki, T.; Matsuura, A.; Kouketsu, A.; Hisakawa, S.; Nakagawa, H.; Miyata, N. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. Bioorg. Med. Chem., 2005, 13, 4332-4342.
166. Malecha, J.; Noble, S. Novel inhibitors of histone deacetylase for the treatment of disease. WO 2006/063294.
167. Ahmed, S.; Combet, C. Mercaptoamides as histone deacetylase inhibitors. WO 2006/028972.
168. Gu, W.; Nusinzon, I.; Smith, Jr., R. D.; Horvath, C. M.; Silverman, R. B. Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. Bioorg. Med. Chem., 2006, 14, 3320-3329.
169. Gibson, K. H.; Stokes, E. S. E. Benzamide compounds. WO 2006/024841 AstraZeneca AB, AstraZeneca UK Ltd.
170. Stokes, E. S. E.; Carr, G. N-(2-Aminophenyl)-4-(5-((ethylamino) methyl) 1,3-thiazol-2-yl) benzamide and N-(2-aminophenyl)-4-(5-((isopropylamino) methyl) 1,3-thiazol-2-yl) benzamide as HDAC inhibitors. WO 2006/064246 AstraZeneca AB, AstraZeneca UK Ltd.
171. Hubbs, J. L.; Mampreian, D. Benzothiophene derivatives. WO 2006/115845 Merck & Co Inc.
172. Bressi, J. C.; Brown, J. W. Histone deacetylase inhibitors. WO 2006/ 066133 Takeda San Diego Inc.
173. Moradei, O.; Leit, S.; Zhou, N.; Fréchette, S.; Paquin, I.; Raeppel, S.; Gaudette, F.; Bouchain, G.; Woo, S. H.; Vaisburg, A.; Fournel, M.; Kalita, A.; Lu, A.; Trachy-Bourget, M.-C.; Yan, P. T.; Liu, J.; Li, Z.; Rahil, J.; MacLeod, A. R.; Besterman, J. M.; Delorme, D. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 4048-4052.
174. Davis, D.; Kim, H. M. Silanol derivatives as inhibitors of histone deacetylase. WO 2006/069096.
175. Attenni, B.; Ferrigno, F. Heterocycle derivatives as histone deacetylase (HDAC) inhibitors. WO 2006/061638.
176. Chakravarty, P. K.; Colletti, S. L. Amide derivatives as inhibitors of histone deacetylase. WO 2006/005955.
177. Jones, P.; Altamura, S.; Chakravarty, P. K.; Cecchetti, O.; De Francesco, R.; Gallinari, P.; Ingenito, R.; Meinke, P. T.; Petrocchi, A.; Rowley, M.; Scarpelli, R.; Serafini, S.; Steinkühler, C. A series of novel, potent, and selective histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5948-5952.
178. Kahnberg, P.; Lucke, A. J.; Glenn, M. P.; Boyle, G. M.; Tyndall, J. D. A.; Parsons, P. G.; Fairlie, D. P. Design, synthesis, potency, and cytoselectivity of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid. J. Med. Chem., 2006, 49, 7611-7622.
179. Belvedere, S.; Hamblett, C. L. Histone deacetylase inhibitors. WO 2006/ 017216.
180. Belvedere, S.; Methot, J. L. Histone deacetylase inhibitors. 2006/017215.
181. Belvedere, S.; Hamblett, C. L. Histone deacetylase inhibitors. 2006/ 026260.
182. Meinke, P. T.; Liberator, P. Histone deacetylase: a target for anti-proliferative and antiprotozoal agents. Curr. Med. Chem., 2001, 8, 211-215.
183. Rodriquez, M.; Terracciano, S.; Cini, E.; Settembrini, G.; Bruno, I.; Bifulco, G.; Taddei, M.; Gomez-Paloma, L. Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222. Angew. Chem., Int. Ed., 2006, 45, 423-427.
184. Mori, H.; Urano, Y.; Abe, F.; Furukawa, S.; Furukawa, S.; Sakai, F.; Hino, M.; Fujii, T. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC) II. Biological activities in animal models. J. Antibiot., 2003, 56, 80-86.
185. Xie, W.; Zou, B.; Pei, D.; Ma, D. Total synthesis of cyclic tetrapeptide FR235222, a potent immunosuppressant that inhibits mammalian histone deacetylases. Org. Lett., 2005, 7, 2775-2777.
186. Bhuiyan, M. P. I.; Kato, T.; Okauchi, T.; Nishino, N.; Maeda, S.; Nihino, T. G.; Yoshida, M. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg. Med. Chem., 2006, 14, 3438-3446.
187. Nakao, Y.; Yoshida, S.; Matsunaga, S.; Shindoh, N.; Terada, Y.; Nagai, K.; Yamashita, J. K.; Ganesan, A.; van Soest, R. W. M.; Fusetani, N. Histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge. Mycale izuensis Angew. Chem., Int. Ed., 2006, 45, 7553-7557.
188. Izzo, I.; Maulucci, N.; Bifulco, G.; De Riccardis, F. Total synthesis of azumamides A and E Angew. Chem., Int. Ed., 2006, 45, 7719-7722.
189. Furumai, R.; Komatsu, Y.; Nishino, N.; Kochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA, 2001, 98, 87-92.
190. Suzuki, T.; Kouketsu, A.; Matsuura, A.; Kohara, A.; Ninomiya, S.; Kohda, K.; Miyata, N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 3313-3317.
191. Suzuki, T.; Kouketsu, A.; Itoh, Y.; Hisakawa, S.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem., 2006, 49, 4809-4812.
192. Mai, A.; Massa, S.; Pezzi, R; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosch, G. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem., 2005, 48, 3344-3353.
193. Masuoka, Y.; Nagai, A.; Shin-ya, K.; Furihata, K.; Nagai, K.; Suzuki, K.; Hayakawa, Y.; Seto, H. Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp. Tetrahedron Lett., 2001, 42, 41-44.
194. Yurek-George, A.; Habens, F.; Brimmell, M.; Packham, G.; Ganesan, A. Total synthesis of spiruchostatin A, a potent histone deacetylase inhibitor. J. Am. Chem. Soc., 2004, 126, 1030-1031.
195. Doi, T.; Iijima, Y.; Kazuo, S. Y.; Ganesan, A.; Takahashi, T. A total synthesis of spiruchostatin. Tetrahedron Lett., 2006, 47, 1177-1180.
196. Packham, G.; Crabb, S. J.; Carey, K.; Yurek-George, A.; Johnson, P. W.; Ganesan, A. Characterisation of spiruchostatin A as an inhibitor of histone deacetylases (HDAC) in breast cancer. Clin. Cancer Res., 2005, 11, 9138S.